Evidence map›Paper›PMID 34110489›Full record

Trial reportJournal of cancer research and clinical oncology2022

Survival predictors of

Mina M Swiha, Duncan E K Sutherland, Golmehr Sistani, Alireza Khatami, Rami M Abazid, Amol Mujoomdar, Daniele P Wiseman, Jonathan G Romsa, Robert H Reid, David T Laidley

Registry-linked trialOpen access · hybridAbstract readClinical Trial, Phase II
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal of cancer research and clinical oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02236910 (An Open Label Phase II, Registry Study of Lutetium-177), which is not on this map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
3.6field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02236910 phase2unknown statusnot on this map

An Open Label Phase II, Registry Study of Lutetium-177 (DOTA0, TYR3) Octreotate (Lu-DOTA-TATE) Treatment in Patients with Somatostatin Receptor Positive Tumours

TypeinterventionalSponsorLondon Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph'sRan2014 to 2025Enrolled66ConditionsNeuroendocrine CarcinomaArmsLu-DOTA-TATE
3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 28 citations in OpenAlex.

  1. Trial
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Single-Time-Point Imaging for Dosimetry After [Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2023
    Article
  9. Diagnostic performance of PET/CT in the detection of liver metastases in well-differentiated NETs.Cancer imaging : the official publication of the International Cancer Imaging Society · 2023
    Article
  10. LutatheraPharmaceutics · 2023
    Review
  11. Review
  12. Article
  13. Review
  14. Neuroendocrine Tumors and Peptide Receptor Radionuclide Therapy: When Is the Right Time?Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2022
    Review
  15. Article
  16. Review
  17. New Insights in PRRT: Lessons From 2021.Frontiers in endocrinology · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Mina M SwihaMedical Imaging Department, Division of Nuclear Medicine, Victoria Hospital, London Health Sciences Centre, University of Western Ontario, 800 Commissioners Road East, PO Box 5010, London, ON, N6A 5W9, Canada. mina.swiha@lhsc.on.ca.ORCID http://orcid.org/0000-0003-3405-7497
Duncan E K SutherlandMedical Imaging Department, Division of Nuclear Medicine, Victoria Hospital, London Health Sciences Centre, University of Western Ontario, 800 Commissioners Road East, PO Box 5010, London, ON, N6A 5W9, Canada.
Golmehr SistaniMedical Imaging Department, Division of Nuclear Medicine, Victoria Hospital, London Health Sciences Centre, University of Western Ontario, 800 Commissioners Road East, PO Box 5010, London, ON, N6A 5W9, Canada.ORCID http://orcid.org/0000-0002-6525-5157
Alireza KhatamiMedical Imaging Department, Division of Nuclear Medicine, Victoria Hospital, London Health Sciences Centre, University of Western Ontario, 800 Commissioners Road East, PO Box 5010, London, ON, N6A 5W9, Canada.ORCID http://orcid.org/0000-0002-6320-7565
Rami M AbazidMedical Imaging Department, Division of Nuclear Medicine, Victoria Hospital, London Health Sciences Centre, University of Western Ontario, 800 Commissioners Road East, PO Box 5010, London, ON, N6A 5W9, Canada.ORCID http://orcid.org/0000-0002-8504-1930
Amol MujoomdarMedical Imaging Department, Division of Diagnostic Radiology, University of Western Ontario, London, ON, Canada.
Daniele P WisemanMedical Imaging Department, Division of Diagnostic Radiology, University of Western Ontario, London, ON, Canada.
Jonathan G RomsaMedical Imaging Department, Division of Nuclear Medicine, Victoria Hospital, London Health Sciences Centre, University of Western Ontario, 800 Commissioners Road East, PO Box 5010, London, ON, N6A 5W9, Canada.
Robert H ReidMedical Imaging Department, Division of Nuclear Medicine, Victoria Hospital, London Health Sciences Centre, University of Western Ontario, 800 Commissioners Road East, PO Box 5010, London, ON, N6A 5W9, Canada.
David T LaidleyMedical Imaging Department, Division of Nuclear Medicine, Victoria Hospital, London Health Sciences Centre, University of Western Ontario, 800 Commissioners Road East, PO Box 5010, London, ON, N6A 5W9, Canada.
Western University · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purpose

methodsA retrospective single-center review was conducted, examining 47 individuals with progressive well-differentiated NETs treated with

resultsMedian follow-up was 63.1 months with a median progression-free survival (PFS) of 34.1 months. However, median overall survival (OS) was not reached at the time of analysis. The presence of ≥ 5 bone metastases (hazard ratio HR 4.33; p = 0.015), non-gastroenteropancreatic (non-GEP) NETs (HR 3.22; p = 0.025) and development of interim ascites (HR 3.15; p = 0.047) independently predicted a worse OS. Patients with chromogranin A of ≥ 4 × upper limit of normal (ULN) had shorter OS (p < 0.001) and PFS (p = 0.004). Similarly, those with pre-existing ascites demonstrated a worse OS (p = 0.009) and PFS (p = 0.026). Liver metastases involving greater than 50% liver volume and the existence of unusual metastatic locations had a negative impact on OS (p = 0.033) and PFS (p = 0.026), respectively.

conclusionHigh burden of skeletal and hepatic metastases, non-GEP-NETs, chromogranin A of ≥ 4 × ULN, unusual metastatic sites, pre-existing and interim ascites are predictors of poor outcomes in patients treated with

trial registrationClinicalTrials.gov identifier: NCT02236910, Retrospectively registered on September, 2014.

Indexed as

AdultAgedAged, 80 and overAntiemeticsAscitesBiomarkers, TumorBone NeoplasmsChromogranin AEndodermFemaleHumansLiver NeoplasmsMaleMiddle AgedNeural CrestNeuroendocrine TumorsAntiemeticsBiomarkers, TumorChromogranin Alutetium Lu 177 dotatateOctreotideOrganometallic CompoundsRadiopharmaceuticalsLu-DotatateNeuroendocrinePrognostic factorsPRRTSurvival predictors

Identifiers

PMID34110489
PMCPMC8752529
OpenAlexW3167530921

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.